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Abstract
Background. Anti-C1q antibodies (anti-C1q) have been
shown to correlate positively with systemic lupus
erythematosus (SLE) nephritis. Several clinical studies
indicated a high negative predictive value, suggesting
that active lupus nephritis is rarely seen in patients with
no anti-C1q. However, the true prevalence of anti-C1q
at the time of active lupus nephritis has not been well
established. The aim of this study was to determine
prospectively the prevalence of anti-C1q in proven
active lupus nephritis at the time of the renal biopsy.
Methods. In this prospective multi-centre study, we
investigated adult SLE patients undergoing renal biopsy
for suspected active lupus nephritis. Serum samples were
taken at the time of the biopsy and analysed for the
presence of anti-C1q in a standardized way. The activity
of lupus nephritis was classified according to the renal
histology. Biopsies were also analysed for the presence
of glomerular IgG, C1q and C3 deposition.
Results. A total of 38 patients fulfilling at least 4/11
American College of Rheumatology (ACR) criteria for
the diagnosis of SLE were included. Out of this, 36
patients had proliferative (class II, III or IV) and two
had class V lupus nephritis. All but one patient with
proliferative lupus nephritis were positive for anti-C1q
(97.2%) compared with the 35% of control SLE
patients with inactive lupus nephritis and 25% of
SLE patients without lupus nephritis ever. All patients
were positive for glomerular C1q (36/36) and 37/38
patients had glomerular IgG deposits. Anti-C1q
strongly decreased during successful treatment.
Conclusions. Anti-C1q have a very high prevalence in
biopsy-proven active lupus nephritis, thus a negative
test result almost excludes active nephritis. The data
support the hypothesis of a pathogenic role of anti-C1q
in lupus nephritis.
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Introduction
An important hypothesis about the pathogenesis of
systemic lupus erythematosus (SLE) assumes that the
disease is driven by a defective clearance of dead and
dying cells (apoptosis) [1]. In the context of an altered
clearance, apoptotic cells could become antigenic
and initiate an autoimmune response. The complement
system has been shown to play an important role in
the clearance of apoptotic cells, and the deficiency of
one of the early components of the classical pathway of
complement, i.e. C1q or C4, is strongly associated with
the development of SLE [2]. However, the majority of
SLE patients has no primary complement deficiency.
In contrast, hypocomplementaemia in SLE patients
is a secondary event and is most often associated
with autoantibodies against C1q (anti-C1q), the first
component of the classical pathway of complement [3].
Anti-C1q are best described in patients with SLE
(reviewed in [4]). In these patients they strongly
correlate with hypocomplementaemia and renal
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flares suggesting that anti-C1q might play a
pathogenic role [5]. It would be plausible that anti-
C1q alter the normal function of the complement system
and consequently impair the course of the disease.
However, the true prevalence of anti-C1q in patients
with active lupus nephritis remains controversial [6].
Whereas most of the clinical studies have shown a
high negative predictive value of anti-C1q for the
occurrence of a severe lupus nephritis ranging up to
100% [7], a more recent study found anti-C1q in only
11/18 patients with proliferative lupus nephritis [8]. The
variation between the studies can be explained in several
ways. First and most importantly, some studies did not
precisely indicate the timing of the anti-C1q test in
relation to the renal flare. Furthermore, the definition of
active lupus nephritis strongly varies between the
studies. Third, the assays used have not been standar-
dized, i.e. every group used its own self-made ELISA
system with different reagents and standards. Last, the
definition of a positive test result varied between the
publications. A high cut-off for a positive result reduced
the sensitivity of the test and consecutively increased the
likelihood of a false negative result. Therefore, in order
to determine the prevalence and negative predictive
value of anti-C1q for the occurrence of proliferative
lupus nephritis, we performed a prospective, multi-
centre study measuring anti-C1q in SLE patients
undergoing renal biopsy for suspected active lupus
nephritis and using a uniform test system [9,10].
Patients and methods
Patients
In this prospective multi-centre study, adult SLE patients
undergoing renal biopsy for suspected proliferative lupus
nephritis were included. The patients were recruited at the
university hospitals in Basel, Geneva, Lausanne, Madrid
(University Hospital La Paz) and Prague (Charles
University). Patients were excluded from the study when
they were <18 years old, did not give written consent or did
not fulfil at least 4 out of the 11 American College of
Rheumatology (ACR) criteria for the diagnosis of SLE [11].
Serum samples had to be taken at the time of the renal biopsy
7 days and were stored at 808C until further use. Renal
histologies obtained were classified according to the
International Society of Nephrology/Renal Pathology
Society [12]. According to the abbreviated version of the
classification, combined classes III/V or IV/V were consid-
ered as class III or IV, respectively. In addition to the
histological classification, biopsy specimens were also stained
for C1q, C3 and IgG. If possible, follow-up serum samples
were taken at months þ6 and þ12 after biopsy.
The study was approved by the Ethical committee of the
University Hospital Basel, Switzerland (EKBB) and con-
formed to standards applied in the involved countries.
Anti-C1q antibodies
Anti-C1q were tested at each participating centre using
the same commercially available ELISA kit according to
the assay procedure (kindly provided by Bu¨hlmann
Laboratories, Scho¨nenbuch, Switzerland). In this assay,
undigested purified human C1q served as the antigen,
and sera were diluted and incubated in a high-salt buffer
(1M NaCl). The optical densities were measured at 450 nm
converted into units (U/ml) by being plotted against
the autoantibody titre of the standards given by the
manufacturer. The upper limit of detection of the assay
was at 400U/ml. The technical cut-off for a positive test
result as determined by the manufacturer (15U/ml) was
obtained by testing samples from 220 normal blood donors.
This cut-off resulted in 14.5% positive blood donors
(32/220). In order to achieve comparability to previous
reports describing that only about 6% of normal blood
donors were anti-C1q positive [3,7,13–16], the cut-off for the
definition of a positive test result was increased to 40U/ml.
This new cut-off was verified in cohorts of other normal
blood donors (n¼ 48), patients with thyroid disease (Graves’
disease, chronic autoimmune thyroiditis or multinodular
goitre, n¼ 60) and patients with ANCA-associated systemic
vasculitis as defined by the presence of high-titre
PR3–ANCA or MPO–ANCA (n¼ 23).
Results in the study population were compared with the
anti-C1q concentrations measured in retrospectively ana-
lysed cohorts of SLE patients without lupus nephritis at any
time (n¼ 36) and SLE patients with biopsy-proven prolif-
erative lupus nephritis (classes II, III or IV) without clinical
activity at the time of the serum sampling (n¼ 26). The SLE
control patients all fulfilled at least 4/11 ACR criteria for the
diagnosis of SLE. The absence of lupus nephritis was defined
as normal urinalysis results and creatinine levels. Inactivity of
pre-existing lupus nephritis was defined as either normal or
continuously decreasing or stable values for proteinuria,
erythrocyturia (<20 erythrocytes/field) and creatinine during
the 6 months preceding the analysis for anti-C1q.
Determination of C1q antigen
C1q antigen determinations were all performed at the
Department of Immunobiology, Hoˆpital Europe´en Georges
Pompidou, Paris, France.
The concentration of C1q antigen in serum was measured
by means of a double-ligand ELISA. Briefly, Nunc
MaxiSorp ELISA plates (Nunc, Roskilde, Denmark) were
coated with goat IgG anti-human C1q (Calbiochem,
Meudon, France). Free reactive sites were blocked with
phosphate-buffered saline (PBS) containing 1% bovine
serum albumin (BSA). The sera to be tested were added at
a dilution of 1:2000 for 1 h. After washing, the plates were
incubated with biotinylated IgG goat anti-human C1q prior
to the addition of streptavidin–horseradish peroxidase and
further incubation for 30min at 378C. Enzymatic activity
was revealed using the orthophenyldiamine substrate.
Values were expressed in percent of the norm
(norm¼ 100%). As a standard for the quantification,
pooled plasma from 100 healthy donors was used. Normal
values established with the plasma from these donors ranged
between 70 and 130% of the reference plasma pool.
Statistics
Non-parametric tests (Mann–Whitney U-test, Spearman’s
rank correlation test) and Fisher’s exact test were used
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throughout using GraphPad Prism versions 3 and 4
(GraphPad Software, San Diego, CA, USA).
Results
Cut-off determination
By the analysis of anti-C1q results of 220 normal blood
donors provided by the manufacturer, the cut-off for
a positive test result was set at >40U/ml resulting in
5.9% positive donors. In order to confirm this cut-off,
the prevalence of anti-C1q was measured in indepen-
dent cohorts of 48 normal blood donors, 60 patients
with thyroid disease and 23 patients with ANCA-
associated vasculitis. In these cohorts, the percentages
of anti-C1q positive individuals were 4.2, 6.7 and 0,
respectively. The results obtained in normal blood
donors were almost identical to those reported
previously [7], and the test specificity similar to that
reported by other groups [3,13–16].
In a second step, 26 SLE patients with a history of
lupus nephritis in the past but without clinical signs of
the activity at the time of serum sampling and 36 SLE
patients without a history of lupus nephritis ever were
analysed for the presence of anti-C1q. In these patients
anti-C1q were found in 35 and 25%, respectively. SLE
patients were significantly more often positive and had
higher titres of anti-C1q than the pooled patients of
non-SLE cohorts. In addition, SLE patients with
inactive lupus nephritis had higher titres of anti-C1q
than those without a history of lupus nephritis ever
(Figure 1).
Anti-C1q in patients with biopsy-proven active lupus
nephritis
A total of 40 patients undergoing renal biopsy for
suspected severe lupus nephritis were included in the
study. Two of these 40 patients had to be excluded for
not fulfilling at least 4 of the 11 ACR criteria for the
diagnosis of SLE. Both the patients were anti-C1q
negative although the renal histology would have been
compatible with class II and IV lupus nephritis,
respectively. These two patients were, moreover,
diagnosed as having C1q nephropathy according to
the criteria described by Jennette and Hipp [17] and
Markowitz et al. [18].
Of the remaining 38 patients, 32 were females and six
males. The age median was 32.5 years (range 19–68).
The histological characteristics are summarized in
Table 1.
The majority of patients had class III or IV lupus
nephritis. All patients had a positive staining for
glomerular C1q and C3, and all but one patient had
a positive staining for glomerular IgG. Anti-C1q were
found in 36/38 patients (94.7%, Figure 1). Two of the
38 patients had class V (membranous) lupus nephritis
corresponding to a class Va nephritis according to the
modified 1982 WHO classification [12]. This entity was
considered as being distinct from the other classes of
lupus nephritis observed in our study population with
regard to prognosis and immunohistological charac-
teristics [17,19]. One of the two patients with membra-
nous lupus nephritis was anti-C1q negative, the other
was low-level positive (Figure 2). Of the remaining 36
patients with class II, III and IV lupus nephritis, all
but one were positive for anti-C1q at the time of the
renal biopsy (97.2%). The results are demonstrated
in Figure 2. SLE patients with proliferative lupus
nephritis were significantly more often positive for
anti-C1q, and the titres were significantly higher than
in SLE controls (P< 0.0001). The only patient being
anti-C1q negative had a 10-year history of cutaneous
lupus erythematosus before developing lupus nephritis
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Fig. 1. Anti-C1q in SLE and control patients. Anti-C1q titres in
cohorts of normal blood donors, patients with thyroid disease and
patients with ANCA-associated vasculitis, compared with SLE
patients without lupus nephritis ever, with clinically inactive lupus
nephritis and patients with lupus nephritis at the time of the biopsy.
SLE patients had significantly higher titres and were more often anti-
C1q positive than pooled control cohorts. In SLE patients, increased
titres of anti-C1q were most frequently detected, and the titres were
highest among patients with active nephritis at the time of the
biopsy. Interestingly, SLE patients with inactive lupus nephritis had
significantly higher anti-C1q titres than those without lupus nephritis
ever.
Table 1. Immunohistological characteristics of the renal biopsy
obtained for suspected proliferative lupus nephritis
Histological
classification
(abbreviated
form)
Numbers
(n¼ 38)
Glomerular
C1q (n¼ 36)
Glomerular
C3 (n¼ 38)
Glomerular
IgG (n¼ 38)
I 0 – – –
II 3 2/2 3/3 3/3
III 10 10/10 10/10 10/10
IV 23 22/22 23/23 22/23
V 2 2/2 2/2 2/2
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accompanied by oral ulcers, arthralgias, anti-nuclear
antibodies (ANA) and anti-dsDNA antibodies. The
patient’s immunohistology was positive for glomerular
C1q and IgG.
For the detection of an active glomerulonephritis in
SLE patients, the anti-C1q assay showed a particularly
high sensitivity (97.2%) and negative predictive
value (97.8%). Specificity and positive predictive
value were 70.3 and 68.4%, respectively. The corre-
sponding receiver operating characteristic (ROC)
curve is demonstrated in Figure 3 [area under the
curve¼ 0.958, 95% confidence interval (CI)
0.92–0.996, P< 0.0001].
Anti-C1q at follow-up
Fifteen of the 36 patients with proliferative lupus
nephritis at biopsy, i.e. classes II, III and IV, could be
followed at 6 months and 11 patients at 12 months
after the biopsy. As demonstrated in Figure 4, there
was a significant drop of anti-C1q titres between the
time of the biopsy and month þ6, but no further
decrease between months þ6 and þ12. In only three
patients, a mild increase of anti-C1q titres at month þ6
could be observed (from 58 to 73, 72 to 91 and 105 to
120U/ml). Furthermore, the two patients with persis-
tently high titres of anti-C1q (>400U/ml) at month
þ6 were the only two of the cohort in whom no
sustained response to treatment could be observed as
judged by the elevated markers of inflammation and
unchanged or reappearing proteinuria and glomerular
erythrocyturia. The patient without response to treat-
ment also had a persistently elevated creatinine
whereas the patient with renal relapse, i.e. reappearing
proteinuria and erythrocyturia after initial improve-
ment, underwent a second biopsy at month þ6
revealing a persistent lupus nephritis class III.
It is interesting to note that the majority of patients
included at the time of the biopsy did not
become negative for anti-C1q during follow-up
despite decreasing titres.
C1q antigen concentrations
Since anti-C1q had been shown to be associated with
low levels of C1q antigen in serum, the sera from the
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Fig. 2. Anti-C1q concentrations according to the class of lupus
nephritis. Anti-C1q titres in the study population of SLE patients at
the time of renal biopsy. Patients were grouped according to the
histological classification of the lupus nephritis. Lupus nephritis
classes II–IV were considered as active (proliferative) forms and
separated from the two patients with class V (membranous) lupus
nephritis. All but one of the patients with proliferative lupus
nephritis (35/36) were anti-C1q positive. Almost half of these
patients (n¼ 14) had very high titres, i.e. 400U/ml.
Fig. 3. ROC curve of anti-C1q for the discrimination between active
and inactive/no lupus nephritis. The ROC curve of the anti-C1q
antibody test used for the discrimination between active and
inactive/no nephritis in SLE patients. The curve was generated
using anti-C1q results from the study population (Figure 2) and the
two SLE control cohorts shown in Figure 1 (area under the
curve¼ 0.958, 95% CI 0.92–0.996, P< 0.0001).
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Fig. 4. Follow-up of anti-C1q in patients with proliferative lupus
nephritis. Anti-C1q titres during follow-up significantly decreased at
6 months after renal biopsy without further decrease at month þ12.
Interestingly, the two patients with persisting high titres of anti-C1q
(400U/ml) at month þ6 did not show a clinical response to
treatment nor had a relapse after initial response as confirmed by a
second biopsy.
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study patients were also analysed for C1q concentra-
tions. Forty-two percent of the sera had C1q con-
centrations below the norm with a median of 76.5%
and a range of 2–145%. As expected, there was a
significant negative correlation between anti-C1q titres
and C1q concentrations in serum (Spearman’s
r¼ 0.426, P< 0.005). The data are demonstrated in
Figure 5.
Discussion
In the present study, we prospectively investigated
the prevalence of autoantibodies against complement
C1q in a cohort of SLE patients undergoing renal
biopsy for suspected proliferative lupus nephritis.
We hypothesized that anti-C1q play an important,
though not exclusive, role in the pathogenesis of lupus
nephritis. Therefore, the majority of patients were
expected to be anti-C1q positive. Indeed, we found a
strong positive correlation between anti-C1q and the
occurrence of active proliferative lupus nephritis. All
but one of the patients with class II, III or IV lupus
nephritis were positive for anti-C1q at the time of
active nephritis, corresponding to a prevalence of
>97%. In comparison, anti-C1q were found in only
about one-third of SLE patients having either inactive
lupus nephritis or no lupus nephritis at all.
Interestingly, the last group had the lowest prevalence
of anti-C1q. In addition to the high prevalence of anti-
C1q in patients with biopsy-proven active lupus
nephritis, these patients had the highest titres observed
in this study. Furthermore, anti-C1q titres strongly
decreased during successful treatment.
The high prevalence of anti-C1q in our patients
might have important consequences for the clinical
management of SLE patients as well as for the
understanding of pathogenic mechanisms in SLE.
From a clinical point of view, anti-C1q might be of
important help in the diagnosis of suspected prolif-
erative lupus nephritis, particularly in situations when
standard parameters such as urinalysis, creatinine,
serum complement levels and anti-dsDNA antibodies
do not allow a clear-cut decision about treatment
modifications and/or the necessity of a renal biopsy.
Very high titres of anti-C1q strongly increase the
likelihood of the presence of severe lupus nephritis.
Vice versa, and maybe more importantly, a negative
test result almost excludes the presence of an active
glomerulonephritis and therefore might help avoid
unnecessary renal biopsies and/or treatment
modifications.
For the judgement about the occurrence of renal
flares in SLE, anti-C1q have been shown to be more
helpful than the determination of anti-dsDNA anti-
bodies [7,20,21]. Furthermore and in contrast to a
previous study using a different technique [8], our data
demonstrate that measuring anti-C1q in the diagnostic
process of active lupus nephritis is also more helpful
than the determination of C1q antigen in serum.
Although there was a strong negative correlation
between anti-C1q and C1q antigen in serum, more
than half of our patients had C1q concentrations
within the normal range.
Up to now, the prevalence of anti-C1q in active
lupus nephritis has not been uniformly established
[6,7]. Although many studies demonstrated a high
prevalence of anti-C1q in active lupus nephritis, the
data presented in other reports suggested lower
negative predictive values for anti-C1q [8,13,22].
Differences between our and previous studies might
be partially attributed to differences in the assay
used and the definition of a positive test result.
In our study we used a well-established [9,10] and
robust commercially available kit that was designed
to well-discriminate low-level positive from negative
results. The cut-off used in our study was set in order
to allow comparisons with previous studies, and
resulted in a low prevalence of anti-C1q in controls.
However, the timing of blood sampling in relation to
the renal flare appears to be the most important
difference with previous studies. It is likely that many
of the negative anti-C1q measurements were from
serum samples that were not obtained shortly before or
during the nephritic episode. Finally, in many studies,
the activity of the nephritis at the time point of blood
sampling was judged by clinical parameters but not
controlled by histology.
Since anti-C1q were detected by an assay using
undigested C1q as the antigen, it might be argued that
some of the positive results are due to unspecific
binding of immune complexes. However, in a previous
report it was demonstrated that binding of immune
complexes is almost completely abrogated by the use of
1M NaCl, and the correlation of results obtained by
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Fig. 5. Correlation between anti-C1q and serum C1q concentrations.
C1q (antigen) concentrations compared with anti-C1q antibody
titres in the SLE patients at the time of the renal biopsy. Although
there was a significant negative correlation between the two
parameters, measuring C1q concentrations was less useful for the
detection of active lupus nephritis than the determination of anti-
C1q since more than half of the patients (58%) had C1q levels within
the norm. C1q concentrations were expressed in percent of norm.
The dotted lines indicate the cut-off for decreased C1q concentra-
tions and elevated titres of anti-C1q, respectively.
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the use of undigested C1q and collagen-like region of
C1q was particularly high (R¼ 0.983) [23]. Therefore,
this factor is unlikely to have substantially affected
our results.
Independent of the clinical relevance of anti-C1q as
a diagnostic parameter, our results support the
hypothesis of anti-C1q playing an important role in
the pathogenesis of lupus nephritis, since all but one
patient were positive for anti-C1q. In a more sensitive
assay, even this patient might have been positive for
anti-C1q [24].
As suggested in a previous study, anti-C1q appear
to be necessary but not sufficient for the occurrence
of severe lupus nephritis [7]. However, the role of anti-
C1q in the pathophysiology of SLE remains unclear.
As the binding of anti-C1q to fluid phase C1q is weak,
their functional role might be limited to tissues/organs
where C1q is deposited, e.g. the kidney [25]. Indeed,
anti-C1q could be isolated from glomerular basement
fragments of patients with proliferative lupus nephritis
and the deposition seemed to occur via binding to
deposited C1q [25,26]. Interestingly, anti-C1q could
not only be isolated from the glomerular basement
membranes of patients with proliferative lupus nephri-
tis but were enriched about 50 times in the glomeruli
compared with the total IgG deposition and anti-C1q
serum concentrations of the same patients.
In a recent experimental study, the effect of a
monoclonal anti-C1q antibody was investigated in
mice [26]. It could be demonstrated that the anti-C1q
alone resulted in glomerular deposition of the antibody
and C1q as well as in mild neutrophil influx but could
not cause severe renal damage. However, when
glomerular immune complexes were induced by a
pre-injection of subnephritogenic doses of a C1q-fixing
anti-glomerular basement membrane (anti-GBM) anti-
body, the following injection of anti-C1q could
exacerbate the pre-existing subclinical renal disease.
Although not being a final proof, the study strongly
supported the view of anti-C1q having a direct
pathogenic effect.
Thus, in the context of our clinical findings, the role
of autoantibodies and B cells should be re-emphasized
in lupus nephritis, with the use of treatment strategies
targeting B cells, such as rituximab, as the logical
consequence.
In conclusion, we found a high prevalence of anti-
C1q in biopsy-proven active lupus nephritis at the time
of the biopsy. The absence of anti-C1q argues strongly
against the presence of proliferative lupus nephritis and
therefore may serve as a tool to avoid unnecessary
renal biopsies and/or treatment intensifications.
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